Last week, biomarker intelligence leaders from Boston-area R&D organizations got a firsthand look at the powerful predictive and prescriptive intelligence that will soon infuse QuartzBio’s AI Biomarker Intelligence Platform, after sharing common challenges facing data-rich precision medicine clinical programs.
Tobi Guennel, PhD, QuartzBio’s Senior Vice President of Product & Chief Architect, energized the Biomarkers & Precision Medicine track at SCOPE 2024 by showing how generative AI can address challenges faced biospecimen and biomarker operations teams, as well as clinical and translational teams, when gathering insights on samples across all parts of a complex biomarker data ecosystem.
Join QuartzBio at SCOPE 2024, the Summit for Clinical Operations Executives, at Booth 300. We’ll be presenting “Tell me what I don’t know: AI-enhanced decisions in biomarker-informed trials” here you’ll learn about deploying generative AI in drug development.
Learn how conversational AI enables you to talk to your biospecimen data. Join Bill Hall for a demo of our virtual Sample Inventory Management solution, powered by an AI-enabled Biomarker Intelligence Platform and intuitive Virtual Assistant.
QuartzBio’s team has deep experience in technology-enabled solutions for the life science industry. In this blog series, we invited you to get to know a member of the QuartzBio team. This month, we are delighted to talk with Katie Berola, Director of virtual Sample Inventory Management.
In a recent article titled, “The Criticality of Specimen Management to Precision Medicine,” Brenda Yanak warned drug developers against minimizing the importance of biospecimens, so often overlooked during biomarker development.
Join Bill Hall for a webinar demo of the QuartzBio® enterprise Biomarker Data Management solution. We’ll show you how to generate patient profiles to view tumor burden over course of treatment, explore multi-marker views of patient profiles, and cross-reference biomarker measures across file types.
Join our webinar to learn how our clients, representing major biopharmas and biotechnology companies, have eliminated tedious data management processes and costly delays with the QuartzBio® virtual Sample Inventory Management SaaS solution.
AI/ML can be a powerful, error-reducing tool for managing clinical sample data as well as biomarker data.
AI/ML-based tools should not replace human judgment, particularly for insight generation, at least until AI/ML-based tools are extensively and rigorously validated (as any piece of critical software would be). Furthermore, regulatory compliance and data privacy are of utmost importance and must be considered when building and using solutions that leverage generative AI frameworks.
However, near-term applications of AI/ML can dramatically improve any tedious process involving a human inspecting data. We list some of these processes in the box below, along with steps we recommend taking to reduce risk in each case.
QuartzBio’s Adam S. Brown, PhD, Senior Director of Product Support, will join experts from Washington University and Dana Farber Cancer Institute in a panel discussion,
“Towards Precision Medicine: Oncological Applications of Data Integration” | May 18, 2:40 PM ET
The panelists will share ideas for how to bring oncologists together with data integration leaders to systematically assess factors contributing to disease.
